Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia

Mauricette Michallet*, Peter Dreger, Mohamad Sobh, Linda Koster, Jennifer Hoek, Ariane Boumendil, Christof Scheid, Christopher P Fox, Gerald Wulf, William Krüger, Michel van Gelder, Paolo Corradini, Domenico Russo, Jakob Passweg, Hélène Schoemans, Wolfgang Bethge, Nicolaas Schaap, Jan Cornelissen, Paul Browne, Nadira DurakovicLutz Muller, Silvia Montoto, Nicolaus Kroger, Johannes Schetelig, French Cooperative Group for CLL, SFGM-TC, and the EBMT Chronic Malignancy and Lymphoma Working Parties

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)884-890
Number of pages7
JournalBone Marrow Transplantation
Volume55
Issue number5
Early online date7 Nov 2019
DOIs
Publication statusPublished - May 2020

Keywords

  • STEM-CELL TRANSPLANTATION
  • HIGH-RISK CLL
  • TARGETING BTK
  • T-CELLS
  • OUTCOMES
  • FAILURE
  • DISEASE

Cite this